RPG Life Sciences
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
RPG Life Sciences is strategically pivoting towards aggressive expansion in the Active Pharmaceutical Ingredient (API) segment, driven by a significant capital infusion and acquisitions aimed at enhancing capacity and market share. Management's focus on high-value products and international growth, particularly in Europe, aligns with Vista's forecast of stable revenue growth and margins. The company's ambitious target of reaching ₹1,000 crore in API revenue, coupled with a return to mid-20% EBITDA margins, reflects a robust long-term growth strategy. However, execution risks related to integration and increased competition in the API market remain critical watchpoints. The favorable macro environment, characterized by improving pricing power and currency depreciation, supports RPG's revenue outlook, although rising input costs could pressure margins. Overall, Vista's expected upside of approximately 6.8% and a target price of ₹2,906 suggest a cautiously optimistic view, contingent on successful execution of the company's strategic initiatives over the next 12-24 months
Why We Like This Stock
- Aggressive expansion strategy in the API segment supported by significant capital investments and acquisitions
- Management's focus on high-value products and international market penetration enhances long-term growth potential
- Favorable macro conditions, including currency depreciation, are expected to boost revenues
Things To Watch Out For
- Execution risks related to the integration of newly acquired units could impact operational efficiency
- Increased competition in the API market may challenge revenue growth and market share
- Rising input costs pose a potential threat to profit margins despite stable revenue expectations
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 582 | 653 | 708 | 738 | 819 |
| Profit Before Tax (Cr.) | 117 | 147 | 150 | 155 | 173 |
| PBT Margin | 20.1% | 22.5% | 21.2% | 21.0% | 21.1% |
| Net Profit (Cr.) | 87 | 115 | 116 | 121 | 134 |
| Earnings Per Share | 52.7 | 69.7 | 70.5 | 73.1 | 81.4 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| ICICI Securities | ▲ Buy | 3,205 | 04-Sep-2026 |
Company Overview
Show Company Profile
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and domestic and international finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology and pediatrics, cardiovascular, pediatrics, neurology, anti-dengue, dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.